T. Lapperre (København NV, Denmark), R. Jordan (Birmingham, United Kingdom), K. Chapman (Toronto, ON, Canada), E. Mekov (Sofia, Bulgaria)
Validation of the GOLD 2017 classification in a Chinese COPD cohort J. Fu (Chengdu, Sichuan, China)
| |
Stability of the exacerbation pattern defined by GOLD 2017 in a real-world COPD population J. Fu (Chengdu, Sichuan, China)
| |
Determinants of re-hospitalizations due to acute exacerbation of COPD M. Erro (Madrid, Spain)
| |
Evaluation of respiratory symptoms in COPD patients from seven Latin America countries: The LASSYC Study M. Miravitlles (Barcelona, Spain)
| |
The prevalence of the chronic obstructive pulmonary disease in the city of Telavi, Georgia: a cross-sectional study. I. Chkhaidze (Tbilisi, Georgia)
| |
BODE INDEX IN DIFFERENT PHENOTYPES OF COPD A. Corlateanu (Chisihau, Republic of Moldova)
| |
Predictors of multiple admissions of COPD patients: about 1167 cases A. Ben Saad (Monastir, Tunisia)
| |
Influence of previous admissions on audit outcomes in patients admitted with acute exacerbation of COPD (AECOPD) J. Holzhauer-Barrie (London, United Kingdom)
| |
Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials D. Singh (Manchester, United Kingdom)
| |
Is diaphragmatic thickness fraction valuable in identifying high-risk chronic obstructive pulmonary disease patients? E. Eryüksel (Istanbul, Turkey)
| |
Discordance between a patient completed COPD Assessment test (CAT) and a CAT completed by patient with physician assistance V. Koblizek (Hradec Králové, Czech Republic)
| |
Association between third-space fluid and FEV1 in COPD patients A. Jimenez Cepeda (saltillo, Mexico)
| |
The Validity of Indonesian Society of Respirology (ISR) Version of COPD Screening Questionnaire Y. Sutanto (surakarta, Indonesia)
| |
Factors acting on the duration of hospitalization in COPD H. Rouis (Tunis, Tunisia)
| |
Comparison between electronic and paper versions of the Evaluating Respiratory Symptoms in COPD (E-RS) and the COPD Assessment Test (CAT). K. Nishimura (Kyoto, Japan)
| |
The prognostic role of the bronchiectasis in patients with COPD E. Kim (Seongnam-si, Republic of Korea)
| |
Differences between GOLD Group C and D: More than mMRC or CAT A. Ben Saad (Monastir, Tunisia)
| |
Level of control of Chronic Obstructive Pulmonary Disease according to clinical phenotypes. Study SINCON A. Baloira (Pontevedra, Spain)
| |
The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials G. Ferguson (Farmington Hills, United States of America)
| |